Top Markets
#1 CyberDEX CyberDEX +391.95%
#2 OVERTAKE OVERTAKE +58.99%
#3 Clearpool Clearpool +25.94%
#4 Playnance Playnance +23.93%
#5 deBridge deBridge +22.97%
#6 B3 (Base) B3 (Base) +20.83%
#7 Nillion Nillion +19.56%
#8 AUKI AUKI +19.09%
#9 Codatta Codatta +17.25%
#10 龙虾 (Lobster) 龙虾 (Lobster) +17.03%
Coin of the day
CyberDEX CyberDEX
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Nuformix plc Nuformix plc

Nuformix plc

NFX
Clasificación en acciones #41013
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes... Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
Precio por acción
$0.00185055
Capitalización bursátil
$48.29K
Cambio (1 día)
-3.55%
Cambio (1 año)
30.31%
País
GB
Comercio Nuformix plc (NFX)

Categoría

Healthcare
Ratio P/B de Nuformix plc (NFX)
Ratio P/B al September 2026 TTM: 2.01
Según los informes financieros más recientes y el precio de las acciones de Nuformix plc, el ratio P/B actual (TTM) es 2.01. Al final de 2024, el ratio P/B era 0.64.
Historial del ratio P/B de Nuformix plc desde 2014 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
2026 (TTM) 2.01 -61.14%
2025 5.17 703.62%
2024 0.64 44.29%
2023 0.45 -63.79%
2022 1.23 -46.40%
2021 2.30 -42.90%
2020 4.02 28.15%
2019 3.14 93.67%
2018 1.62 -108.69%
2017 -18.66 -793.31%
2016 2.69 0.00%
2014 0.00 0.00%
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.5144 224.23%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 8.5918 327.62%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 3.9974 98.95%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 7.3983 268.22%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH